AstraZeneca PLC — Director's Dealing 2017

Dec 28, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4358A

AstraZeneca PLC

28 December 2017

28 December 2017 14:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL

RESPONSIBILITIES - AMENDMENT

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements of the EU Market Abuse Regulation on 15 December 2017 relating to a change in the beneficial interest in the Company's Ordinary Shares of US$0.25 each of Mr Soriot has been amended, as set out in the revised notification below.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Pascal Soriot

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Amendment

- Previous notification reference number: 00031829

- Effective date of transfer amended from 13 December 2017

- Number of shares transferred amended from 40,148

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

AstraZeneca PLC

b)

LEI

PY6ZZQWO2IZFZC3IOL08

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

GB0009895292

b)

Nature of the transaction

Gift of shares to family members for nil consideration

c)

Price(s) and volume(s)

Price(s)	Volume(s)
0	39,648

d)

Aggregated information

- Aggregated volume

- Price

Not applicable - single transaction

e)

Date of the transaction

27 December 2017

f)

Place of the transaction

Outside a trading venue

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler	UK/Global	+44 203 749 5638
Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Gonzalo Viña	UK/Global	+44 203 749 5916
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	+1 302 885 2677
Investor Relations
Thomas Kudsk Larsen		+44 203 749 5712
Craig Marks	Finance, Fixed Income, M&A	+44 7881 615 764
Henry Wheeler	Oncology	+44 203 749 5797
Mitchell Chan	Oncology; Other	+1 240 477 3771
Christer Gruvris	Brilinta; Diabetes	+44 203 749 5711
Nick Stone	Respiratory; Renal	+44 203 749 5716
US toll free		+1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUWSWRBWAUURA